The American Journal of Medicine
Volume 120, Issue 4, Supplement 1 , Pages S32-S35 , April 2007

Healthcare Policy Implications of Heterogeneity of Treatment Effects

  • Michael J. McLaughlin, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Michael J. McLaughlin, MD, Peloton Advantage, 1719 Route 10, Suite 216, Parsippany, New Jersey 07054.
    • ,
  • members of the HTE Policy Roundtable Panel

      Affiliations

    • A complete list of panel members and their affiliations appears in the Appendix.

References 

  1. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82:661–687
  2. Goldstein DB, Need AC, Singh R, Sisodiya SM. Potential genetic causes of heterogeneity of treatment effects. Am J Med. 2007;120:S21–S25
  3. Greenfield S, Kravitz R, Duan N, Kaplan SH. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med. 2007;120:S3–S9
  4. Materson BJ. Variability in response to antihypertensive drugs. Am J Med. 2007;120:S10–S20
  5. Stroup TS. Heterogeneity of treatment effects in schizophrenia. Am J Med. 2007;120:S26–S31
  6. Schinkel J, Spaan WJ, Kroes AC. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. Antivir Ther. 2004;9:275–286
  7. Meadows M. FDA approves heart drug for black patients. FDA Consum. 2005;39:8–9
  8. Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology. 2002;123:1686–1701

PII: S0002-9343(07)00139-8

doi: 10.1016/j.amjmed.2007.02.006

The American Journal of Medicine
Volume 120, Issue 4, Supplement 1 , Pages S32-S35 , April 2007

Article Tools